SBLOF (Shin Nippon Biomedical Laboratories) Revenue: $213.5 Mil (TTM As of Mar. 2026)


SBLOF Shin Nippon Biomedical Laboratories Ltd SBLOF
74 GF Score
Price $9.16
GF Value $14.04
! 5 Warning Signs
View Full Analysis

What is Shin Nippon Biomedical Laboratories Revenue?

Shin Nippon Biomedical Laboratories SBLOF -2.13% 74 Revenue is $213.5 Mil as of Mar. 2026. GuruFocus rates SBLOF with a GF Score™ of 74/100 and a GF Value™ of $14.04. The stock has 5 warning signs investors should review.

Shin Nippon Biomedical Laboratories's revenue for the three months ended in Mar. 2026 was $71.4 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $213.5 Mil. Shin Nippon Biomedical Laboratories's Revenue per Share for the three months ended in Mar. 2026 was $1.72. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $5.13.

Warning Sign:

Shin Nippon Biomedical Laboratories Ltd revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Shin Nippon Biomedical Laboratories was 0.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 9.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 17.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Shin Nippon Biomedical Laboratories's highest 3-Year average Revenue per Share Growth Rate was 22.20% per year. The lowest was -9.80% per year. And the median was -2.50% per year.


Shin Nippon Biomedical Laboratories  (OTCPK:SBLOF) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Shin Nippon Biomedical Laboratories Revenue Related Terms


Shin Nippon Biomedical Laboratories Revenue Historical Data

* Premium members only.

The historical data trend for Shin Nippon Biomedical Laboratories's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shin Nippon Biomedical Laboratories Revenue Chart

Shin Nippon Biomedical Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 149.68 187.72 176.55 217.46 204.97

Shin Nippon Biomedical Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.29 44.83 56.06 41.24 71.40

SBLOF vs TMO, DHR, IDXX: Revenue Comparison

For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shin Nippon Biomedical Laboratories Revenue vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Revenue distribution charts can be found below:

* The bar in red indicates where Shin Nippon Biomedical Laboratories's Revenue falls into.


SBLOF
74GF Score
Shin Nippon Biomedical Laboratories Ltd SBLOF
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shin Nippon Biomedical Laboratories Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $213.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $213.5 Mil mean?
Shin Nippon Biomedical Laboratories (SBLOF) has a Revenue of $213.5 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Shin Nippon Biomedical Laboratories and its competitors.
Is Shin Nippon Biomedical Laboratories' Revenue too high?
Shin Nippon Biomedical Laboratories' current Revenue is $213.5 Mil. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Revenue compare to TMO and DHR?
Shin Nippon Biomedical Laboratories' Revenue of $213.5 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Diagnostics & Research company?
A good Revenue depends on the Medical Diagnostics & Research industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Shin Nippon Biomedical Laboratories and its competitors. Shin Nippon Biomedical Laboratories's current Revenue is $213.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current Revenue of $213.5 Mil. The stock's GF Value™ is $14.04, compared to a current price of $9.16 — trading 34.8% below its estimated fair value. The current Revenue is $213.5 Mil. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current Revenue is $213.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?

Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued. The current stock price of $9.16 is trading 34.8% below its estimated GF Value™ of $14.04.

Key valuation signals for SBLOF:

  • Revenue: $213.5 Mil
  • GF Value™: $14.04 vs. price of $9.16 (34.8% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shin Nippon Biomedical Laboratories Business Description

Other Exchanges 2395:JapanYB3:Germany
Address 8-1 Akashi-cho, Tokyo, JPN
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score

Get the complete analysis for SBLOF

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.16
Price
$14.04
GF Value